BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the granting of restricted stock units (RSUs) to eight newly-hired employees. The compensation committee approved a total of 57,000 shares of BioCryst common stock as inducement awards on July 1, 2025.
The RSUs will vest over four years in equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. These grants were made under Nasdaq Listing Rule 5635(c)(4) and are subject to BioCryst's Inducement Equity Incentive Plan terms.
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha annunciato l'assegnazione di unità azionarie vincolate (RSU) a otto nuovi dipendenti. Il comitato per la remunerazione ha approvato un totale di 57.000 azioni ordinarie di BioCryst come premi di incentivazione il 1° luglio 2025.
Le RSU matureranno in quattro anni con rate annuali uguali, a partire dal primo anniversario della data di assegnazione, a condizione che il rapporto di lavoro continui. Questi premi sono stati concessi in conformità alla Regola 5635(c)(4) del Nasdaq e sono soggetti ai termini del Piano di Incentivi Azionari di BioCryst.
BioCryst Pharmaceuticals (Nasdaq: BCRX) anunció la concesión de unidades de acciones restringidas (RSU) a ocho empleados recientemente contratados. El comité de compensación aprobó un total de 57,000 acciones ordinarias de BioCryst como premios de incentivo el 1 de julio de 2025.
Las RSU se consolidarán durante cuatro años en cuotas anuales iguales, comenzando desde el primer aniversario de la fecha de concesión, condicionado a la continuidad en el empleo. Estas concesiones se realizaron bajo la Regla 5635(c)(4) del Nasdaq y están sujetas a los términos del Plan de Incentivos de Capital de BioCryst.
BioCryst Pharmaceuticals (나스닥: BCRX)는 신규 채용된 8명의 직원에게 제한 주식 단위(RSU)를 부여했다고 발표했습니다. 보상 위원회는 2025년 7월 1일에 BioCryst 보통주 57,000주를 유인 보상으로 승인했습니다.
RSU는 부여일로부터 1년 후 첫 번째 기념일부터 시작하여 4년 동안 매년 동일한 비율로 베스팅되며, 계속 고용 조건이 충족되어야 합니다. 이 보상은 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌으며 BioCryst의 유인 주식 인센티브 계획 조건에 따릅니다.
BioCryst Pharmaceuticals (Nasdaq : BCRX) a annoncé l'octroi d'unités d'actions restreintes (RSU) à huit nouveaux employés. Le comité de rémunération a approuvé un total de 57 000 actions ordinaires de BioCryst en tant que récompenses d'incitation le 1er juillet 2025.
Les RSU seront acquises sur une période de quatre ans par versements annuels égaux, à compter du premier anniversaire de la date d'octroi, sous réserve de la poursuite de l'emploi. Ces attributions ont été effectuées conformément à la règle 5635(c)(4) du Nasdaq et sont soumises aux termes du plan d'incitation en actions de BioCryst.
BioCryst Pharmaceuticals (Nasdaq: BCRX) gab die Gewährung von Restricted Stock Units (RSUs) an acht neu eingestellte Mitarbeiter bekannt. Der Vergütungsausschuss genehmigte am 1. Juli 2025 insgesamt 57.000 Aktien der BioCryst-Stammaktien als Anreizprämien.
Die RSUs werden über vier Jahre in gleichen jährlichen Raten ab dem einjährigen Jubiläum des Gewährungsdatums vesten, vorbehaltlich der fortgesetzten Beschäftigung. Diese Zuteilungen erfolgten gemäß Nasdaq Listing Rule 5635(c)(4) und unterliegen den Bedingungen des BioCryst Inducement Equity Incentive Plans.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) covering an aggregate of 57,000 shares of BioCryst common stock. The RSUs were granted as of July 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
FAQ
What type of stock compensation did BioCryst (BCRX) grant to new employees in July 2025?
How do the RSUs vest for BioCryst's (BCRX) new employees?
Under what regulation were BioCryst's (BCRX) inducement grants made?
How many new employees received RSU grants from BioCryst (BCRX)?
